5 medtech trends to watch in 2024

From the M&A outlook and tough year-over-year comparisons to emerging markets like pulsed field ablation, here are the top medical technology trends to watch this year.

By Ricky Zipp • Jan. 9, 2024

Boston Scientific to buy Axonics for $3.7B to gain incontinence treatment

The acquisition provides a high-growth addition to Boston Scientific’s urology business, analysts said.

By Susan Kelly • Jan. 8, 2024

Explore the Trendline➔

MedTech Dive Outlook 2022

The pandemic continues to disrupt the medical device industry early in 2022, as COVID-19 testing demand remains strong and nonemergent procedures are postponed. In this series, we look at the risks, challenges and opportunities ahead.

By MedTech Dive staff

‘Healthy pullback’: GSR Ventures’ Sunny Kumar on normalizing digital health funding, accelerating M&A in 2024

Sunny Kumar discusses digital healthcare investment, the landscape for M&A and when the public markets could open back up. 

By Emily Olsen • Jan. 8, 2024

Roche to buy LumiraDx’s point-of-care technology for $295M

LumiraDx faces financial pressures amid declining test sales and a potential delisting from the Nasdaq.

By Elise Reuter • Jan. 2, 2024

Roundup: Illumina’s long goodbye to cancer test maker Grail

From the start, the DNA sequencing leader faced pressure to unwind its $8 billion acquisition of the cancer screening developer. As 2023 drew to a close, it has finally agreed.

By Susan Kelly • Dec. 21, 2023

Stryker buys joint replacement business Serf Sas

The purchase is expected to complement Stryker’s business in Europe and its joint replacement portfolio.

By Elise Reuter • Dec. 20, 2023

Roundup: Medtech M&A slump continues but analysts predict uptick in 2024

Globus Medical and Thermo Fisher were among the companies to announce billion dollar deals this year, while Medtronic and Boston Scientific called off acquisitions.

By Nick Paul Taylor • Dec. 19, 2023

Illumina to part with Grail, ending battle with regulators

Activist investor Carl Icahn, who is suing the company over its acquisition of Grail, continued to push for the removal of several board members in a letter to fellow shareholders.

By Susan Kelly • Dec. 18, 2023

Zimvie to sell spine business for $375M

Zimvie said the sale to H.I.G. Capital will leave the company focused on its dental business and help reduce debt.

By Elise Reuter • Dec. 18, 2023

Integra to buy J&J’s Acclarent for $275M

Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures.

By Elise Reuter • Dec. 13, 2023

Illumina prepares to divest Grail with Form 10 filing

The DNA sequencer is preparing to unwind its 2021 acquisition of the liquid biopsy test maker while still appealing orders to do so from regulators in the U.S. and Europe.

By Susan Kelly • Dec. 13, 2023

Edwards to spin off its critical care business

Edwards is the latest healthcare firm to spin off a business to focus on specific markets, following larger companies like Johnson & Johnson and GE.

By Ricky Zipp • Dec. 8, 2023

J&J heats up LAA closure competition with $400M Laminar buy

Just days after Medtronic announced it would launch a LAA device, J&J said it has acquired a company that is developing a new treatment for LAA closure.

By Susan Kelly • Nov. 30, 2023

3 medtech spinoffs that reshaped the industry in 2023, and what to expect next

GE HealthCare, Johnson & Johnson and Danaher completed transactions this year. Baxter, 3M and Medtronic are now on deck.

By Susan Kelly • Nov. 29, 2023

Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant

Bioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew.

By Nick Paul Taylor • Nov. 27, 2023

4 takeaways from Stryker’s investor day

The company’s expected return to pre-pandemic operating margins, procedure backlogs and weight loss drugs were among the topics discussed at Wednesday’s event.

By Elise Reuter • Nov. 9, 2023

Inari Medical to buy limb-saving device maker LimFlow for up to $415M

The deal includes $250 million in cash upfront and additional payments based on reaching commercial and reimbursement milestones.

By Susan Kelly • Nov. 3, 2023

CooperCompanies buys reproductive health products from Cook Medical after failed takeover

The company paid $300 million to buy certain maternal fetal medicine and gynecological surgery products. 

By Elise Reuter • Nov. 2, 2023

Thermo Fisher buys Olink Holding for $3.1B, pushing further into proteomics

Olink’s high-throughput protein analysis technology is expected to complement Thermo Fisher’s mass spectrometry and life sciences platforms.

By Susan Kelly • Oct. 17, 2023

Illumina details EC timeline, funding requirements for Grail divestment

The European Commission ordered the gene sequencing company to support Grail with two-and-a-half years of funding if it pursues a spinoff.

By Susan Kelly • Oct. 13, 2023

Getinge inks $320M Healthmark takeover to bolster US sterile reprocessing capabilities

Buying Healthmark strengthens the position of Getinge in the U.S., building on two recent acquisitions of sterile reprocessing technology.

By Nick Paul Taylor • Oct. 12, 2023

How Medtronic, Zimmer Biomet and Smith & Nephew are thinking about acquisitions, spinoffs

Executives from the three medical device firms said they expect more deal-making in the long term, but face tough discussions about valuations with targets.

By Elise Reuter • Oct. 11, 2023

Haemonetics inks $253M OpSens buyout, adding cardiology guidewires to portfolio

The takeover will give Haemonetics devices that complement its vascular closure products, analysts said.

By Nick Paul Taylor • Oct. 11, 2023

5 financial challenges facing the medtech sector: EY

Declining stock prices, M&A, investment and revenues are dogging the industry in a difficult year, according to a new report from the consulting firm.

By Elise Reuter • Oct. 10, 2023

J&J could reach market-leading medtech growth after consumer spinoff: analysts

The analysts identified J&J’s leadership position in 11 categories, shift to fast-growing markets and investment in robotics as strengths.

By Nick Paul Taylor • Oct. 9, 2023